Scheduled Maintenance
We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.
ARCADIA BIOSCIENCES INC (RKDA)
US0390143032 - Common Stock
Taking everything into account, RKDA scores 4 out of 10 in our fundamental rating. RKDA was compared to 92 industry peers in the Food Products industry. No worries on liquidiy or solvency for RKDA as it has an excellent financial health rating, but there are worries on the profitability. RKDA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RKDA had negative earnings in the past year.
In the past year RKDA has reported a negative cash flow from operations.
RKDA had negative earnings in each of the past 5 years.
RKDA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -70.96%, RKDA is doing worse than 90.11% of the companies in the same industry.
RKDA has a worse Return On Equity (-108.89%) than 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.96% | ||
| ROE | -108.89% | ||
| ROIC | N/A |
ROA(3y)-52.5%
ROA(5y)-51.16%
ROE(3y)-76.39%
ROE(5y)-123.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 46.53%, RKDA belongs to the best of the industry, outperforming 97.80% of the companies in the same industry.
RKDA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for RKDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.48%
GM growth 5Y-3.26%
2. Health
2.1 Basic Checks
RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKDA has more shares outstanding than it did 1 year ago.
RKDA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RKDA has an Altman-Z score of -20.36. This is a bad value and indicates that RKDA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.36, RKDA is doing worse than 94.51% of the companies in the same industry.
RKDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.36 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
RKDA has a Current Ratio of 4.17. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
RKDA has a better Current ratio (4.17) than 89.01% of its industry peers.
RKDA has a Quick Ratio of 3.63. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
RKDA has a Quick ratio of 3.63. This is amongst the best in the industry. RKDA outperforms 94.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.17 | ||
| Quick Ratio | 3.63 |
3. Growth
3.1 Past
RKDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.51%, which is quite impressive.
RKDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.51%.
RKDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.56% yearly.
EPS 1Y (TTM)35.51%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q59.94%
Revenue 1Y (TTM)-30.51%
Revenue growth 3Y-12.77%
Revenue growth 5Y29.56%
Revenue growth Q2Q17%
3.2 Future
RKDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.56% yearly.
Based on estimates for the next years, RKDA will show a quite strong growth in Revenue. The Revenue will grow by 13.14% on average per year.
EPS Next Y67.22%
EPS Next 2Y31.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.39%
Revenue Next 2Y13.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
RKDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RKDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RKDA's earnings are expected to grow with 31.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.56%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for RKDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCADIA BIOSCIENCES INC
NASDAQ:RKDA (5/3/2024, 7:15:50 PM)
1.955
-0.03 (-1.76%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.96% | ||
| ROE | -108.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.17 | ||
| Quick Ratio | 3.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)35.51%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y67.22%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-30.51%
Revenue growth 3Y-12.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y